Intellia Therapeutics (NTLA) Receivables - Other (2015 - 2023)

Intellia Therapeutics (NTLA) has 9 years of Receivables - Other data on file, last reported at $1.0 million in Q4 2023.

• On a quarterly basis, Receivables - Other fell 37.5% year-over-year to $1.0 million in Q4 2023; TTM through Dec 2023 was $1.0 million, a 37.5% decrease from a year earlier, with the FY2023 full-year figure at $1.0 million, down 37.5% from the prior year.
• Receivables - Other for Q4 2023 stood at $1.0 million, roughly flat from $1.0 million in the prior quarter.
• Over the last five years, Receivables - Other for NTLA reached as high as $8.4 million in Q1 2020 and fell as low as $100000.0 in Q4 2021.
• Historically, Receivables - Other has averaged $2.1 million across 5 years, with a median of $1.4 million in 2023.
• Across the five-year window, Receivables - Other slumped 95.24% in 2021 and jumped 1500.0% in 2022, its largest moves.
• Year by year, Receivables - Other stood at $3.6 million in 2019, then sank by 41.67% to $2.1 million in 2020, then slumped by 95.24% to $100000.0 in 2021, then soared by 1500.0% to $1.6 million in 2022, then plunged by 37.5% to $1.0 million in 2023.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.0 million in Q4 2023, $1.0 million in Q3 2023, and $1.4 million in Q2 2023.